Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y3A4
UPID:
RRP7A_HUMAN
Alternative names:
Gastric cancer antigen Zg14
Alternative UPACC:
Q9Y3A4; A4FTX2; B2RBG4; Q0VAD0; Q5JZ94; Q6P4B5; Q8IVR9; Q8IVY0; Q8N5Q3; Q8NEY6; Q9Y3H5
Background:
Ribosomal RNA-processing protein 7 homolog A, also known as Gastric cancer antigen Zg14, plays a crucial role in ribosomal RNA processing and is pivotal in neurogenesis and neocortex development. It is part of the small subunit processome, facilitating RNA folding, modifications, and cleavage, essential for ribosome biogenesis.
Therapeutic significance:
Linked to Microcephaly 28, primary, autosomal recessive, characterized by significantly reduced head size and impaired intellectual development, understanding the role of Ribosomal RNA-processing protein 7 homolog A could open doors to potential therapeutic strategies.